Innate Pharma : Cash position of € 141.6m in H1 2018
>H1 2018 results - Innate Pharma just published its figures for H1 2018. Operating income in the period came to € 23.7m (vs € 21.2m in H1 2017) mainly comprising: i/ revenues from collaboration and licensing agreements of € 16.9m; and ii/ a research tax credit of € 6.2m. The operating loss was flat at 1e€ 15.7m (versus -€ 15.9m in 2017) for a net loss of -€ 16.2m. The cash position at the end of June 2018 stood at € 141.6m versus € 176.6m at end-2017. Dens...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.